Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia

A Phase 2, Randomized, Open-Label, Dose Titration, Efficacy and Safety Study of FG-4592 (Roxadustat) in Non-Dialysis Chronic Kidney Disease Patients With Anemia

The primary purpose of this study is to evaluate efficacy and safety of roxadustat in the correction of anemia in participants with non-dialysis chronic kidney disease.

Study Overview

• Status: Completed
• Conditions: Anemia; Chronic Kidney Disease
• Intervention / Treatment: Drug: Roxadustat

• Study Type: Interventional
• Enrollment (Actual): 145
• Phase: Phase 2

Contacts and Locations

Study Locations

• Puerto Rico
  • Caguas, Puerto Rico
  • Ponce, Puerto Rico
  • San Juan, Puerto Rico
• United States
  • Alabama
    • Mobile, Alabama, United States
  • Arkansas
    • Pine Bluff, Arkansas, United States
  • California
    • Azusa, California, United States
    • Chula Vista, California, United States
    • Downey, California, United States
    • Northridge, California, United States
    • Paramount, California, United States
    • Riverside, California, United States
    • Whittier, California, United States
    • Yuba City, California, United States
  • Florida
    • Fort Lauderdale, Florida, United States
    • Lauderdale Lakes, Florida, United States
    • Pembroke Pines, Florida, United States
    • Tampa, Florida, United States
  • Georgia
    • Augusta, Georgia, United States
  • Idaho
    • Meridian, Idaho, United States
  • Kansas
    • Wichita, Kansas, United States
  • Louisiana
    • Baton Rouge, Louisiana, United States
    • Shreveport, Louisiana, United States
  • Maryland
    • Bethesda, Maryland, United States
  • Michigan
    • Detroit, Michigan, United States
  • Nebraska
    • Lincoln, Nebraska, United States
  • New Jersey
    • Mount Laurel, New Jersey, United States
  • New York
    • Mineola, New York, United States
    • New York, New York, United States
  • North Carolina
    • Asheville, North Carolina, United States
    • Raleigh, North Carolina, United States
  • Ohio
    • Canton, Ohio, United States
  • South Carolina
    • Orangeburg, South Carolina, United States
  • Tennessee
    • Knoxville, Tennessee, United States
  • Texas
    • Arlington, Texas, United States
    • Fort Worth, Texas, United States
    • Houston, Texas, United States
    • San Antonio, Texas, United States
  • Virginia
    • Fairfax, Virginia, United States

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Age 18 to 75 years
2. Chronic kidney disease, not receiving dialysis
3. Body weight 45 to 140 kg

Exclusion Criteria:

1. Any clinically significant infection or evidence of an underlying infection
2. Positive for any of the following: human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus antibody (anti-HCV Ab)
3. History of chronic liver disease
4. New York Heart Association Class III or IV congestive heart failure
5. Myocardial infarction or acute coronary syndrome within 12 weeks prior to randomization
6. History of malignancy
7. Chronic inflammatory disease that could impact erythropoiesis (for example, systemic lupus erythematosis, rheumatoid arthritis, celiac disease) even if it is currently in remission
8. History of myelodysplastic syndrome, multiple myeloma, or pure red cell aplasia
9. History of hemosiderosis, hemochromatosis or polycystic kidney disease
10. Active hemolysis or diagnosis of hemolytic syndrome
11. Uncontrolled or symptomatic secondary hyperparathyroidism
12. Seizure disorder or receiving anti-epilepsy medication
13. Known bone marrow fibrosis
14. Any prior or scheduled organ transplant
15. Prior treatment with roxadustat or any hypoxia-inducible factor prolyl hydroxylase inhibitor
16. History of alcohol or drug abuse

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort A: Roxadustat Tiered, Weight Based Dosing TIW; Participants will receive roxadustat capsules, administered orally 3 times weekly (TIW) for 16 weeks. Initial roxadustat dose will be based on a tiered, weight-based dosing scheme (low-weight [45 to 60 kilograms (kg)], medium-weight [>60 to 90 kg], and heavy-weight [>90 to 140 kg] participants will receive 60, 100, and 140 milligrams [mg] roxadustat, respectively). Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.2 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 11-13 g/dL.	Drug: Roxadustat; Oral capsule; Other Names: FG-4592
Experimental: Cohort B: Roxadustat Tiered, Weight Based Dosing TIW then BIW; Participants will receive roxadustat capsules orally for 16 weeks. Initial roxadustat dose will be based on a tiered, weight-based dosing scheme (low-weight [45 to 60 kg], medium-weight [>60 to 90 kg], and heavy-weight [>90 to 140 kg] participants will receive 60, 100, and 140 mg roxadustat, respectively). Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.2 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 11-13 g/dL. Participants will have a dose frequency reduction from TIW to 2 times a week (BIW) at the time of the initial Hb response.	Drug: Roxadustat; Oral capsule; Other Names: FG-4592
Experimental: Cohort C: Roxadustat at 50 mg TIW; Participants will receive roxadustat capsules at 50 mg, administered orally TIW for 24 weeks. Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.2 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 10.5-12 g/dL.	Drug: Roxadustat; Oral capsule; Other Names: FG-4592
Experimental: Cohort D: Roxadustat at 100 mg TIW; Participants will receive roxadustat capsules at 100 mg, administered orally TIW for 24 weeks. Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.2 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 10.5-12 g/dL.	Drug: Roxadustat; Oral capsule; Other Names: FG-4592
Experimental: Cohort E: Roxadustat Tiered, Weight Based Dosing BIW then QW; Participants will receive roxadustat capsules for 24 weeks. Initial roxadustat dose will be based on a tiered, weight-based dosing scheme (low-weight [45 to 60 kg], medium-weight [>60 to 90 kg], and heavy-weight [>90 to 140 kg] participants will receive 70, 100, and 150 mg roxadustat, respectively). Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.5 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 11-13 g/dL. Participants will have a dose frequency reduction from BIW to 1 time a week (QW) at the time of the initial Hb response.	Drug: Roxadustat; Oral capsule; Other Names: FG-4592
Experimental: Cohort F: Roxadustat at 70 mg BIW then QW; Participants will receive roxadustat capsules at 70 mg for 24 weeks. Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.5 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 11-13 g/dL. Participants will have a dose frequency reduction from TIW to BIW at the time of the initial Hb response. Then after >8 weeks of stable Hb, dose frequency will be reduced from BIW to QW.	Drug: Roxadustat; Oral capsule; Other Names: FG-4592

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number (%) of Participants With an Hb Response by Week 17	An Hb response was defined as a Hb level of ≥11 g/dL and an increase from BL ≥1 g/dL.	Up to Week 17

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number (%) of Participants With an Hb Response by Weeks 5, 9, 13, 17, 21, and 25	An Hb response was defined as a Hb level of ≥11 g/dL and an increase from BL ≥1 g/dL.	Up to Weeks 5, 9, 13, and 17 (all cohorts) and Weeks 21 and 25 (24-week treatment cohorts only)
Change From Baseline in Hb at Weeks 5, 9, 13, 17, 21, and 25	Baseline is defined as the mean of the last 3 available values predose.	Baseline, Weeks 5, 9, 13, and 17 (all cohorts) and Weeks 21 and 25 (24-week treatment cohorts only)
Number (%) of Participants With Mean Hb Between 11-12, 11-13, and 10.5-13 g/dL During Weeks 5-8, 9-12, 9-16, 13-16, 17-20, 17-24, 21-24, and 25-28	Participants can have a Hb value reported for more than 1 of the categories (11-12, 11-13, and 10.5-13 g/dL) during the week intervals since these categories are not mutually exclusive.	Weeks 5-8, 9-12, 9-16, 13-16, and 17-20 (all cohorts) and Weeks 17-24, 21-24, and 25-28 (24-week treatment cohorts only)
Number (%) of Participants With 2 Consecutive Hb Values Between 11-12, 11-13, and 10.5-13 g/dL During Weeks 5-8, 9-12, 13-16, 9-16, 17-20, 17-24, 21-24, and 25-28		Weeks 5-8, 9-12, 9-16, 13-16, and 17-20 (all cohorts) and Weeks 17-24, 21-24, and 25-28 (24-week treatment cohorts only)
Number (%) of Participants Who Achieve Maximum Hb Between 11-12, 11-13, and 10.5-13 g/dL by Weeks 5, 9, 13, 17, 21, and 25	Participants can have a Hb value for the same category (11-12, 11-13, or 10.5-13 g/dL) reported for multiple weeks.	Weeks 5, 9, 13, and 17 (all cohorts) and Weeks 21 and 25 (24-week treatment cohorts only)
Number (%) of Participants With Maximum Hb <11, >12, >13, and >14 g/dL During Weeks 5-8, 9-12, 9-16, 13-16, 17-20, 17-24, 21-24, and 25-28		Weeks 5-8, 9-12, 9-16, 13-16, and 17-20 (all cohorts) and Weeks 17-24, 21-24, and 25-28 (24-week treatment cohorts only)
Median Time to Hb Response: Hb Increase ≥1 g/dL From Baseline and Hb ≥11 g/dL	Median time to response was estimated using Kaplan Meier method, Cohort A and B censored at Week 17, Cohort C, D, E, and F censored at Week 25. The median number of days presented was calculated from Baseline to the day the Hb response was achieved.	Up to Week 17 (Cohorts A and B) and up to Week 25 (Cohorts C-F)
Median Initial Hb Responsive Time: Time to Initial Hb Increase ≥1.0 g/dL From Baseline	Median time to response was estimated using Kaplan Meier method; Cohort A and B censored at Week 17 and Cohort C, D, E, and F censored at Week 25. The median number of days presented was calculated from Baseline to the day the Hb response was achieved.	Up to Week 17 (Cohorts A and B) and up to Week 25 (Cohorts C, D, E, and F)
Median Initial Hb Responsive Dose: Dose at Which Initial Hb Increases to ≥1.0 g/dL From Baseline		Up to Week 17 (Cohorts A and B) and up to Week 25 (Cohorts C-F)
Change in Hb After Reaching a Hb Response of ≥11.0 g/dL and an Increase in Hb by ≥1.0 g/dL by Week		Cohorts A and B: Weekly through Week 16 (end of treatment), Week 18 (2 weeks posttreatment), and Week 20 (4 weeks posttreatment); Cohorts C-F: Weekly through Week 24 (end of treatment), Week 26 (2 weeks posttreatment), and Week 28 (4 weeks posttreatment)
Mean Hb Values From Participants Who Reached Hb >11.0 g/dL in the Hb 11-12, 11-13, and 10.5-13 g/dL Categories		Cohorts A and B: Weekly through Week 16 (end of treatment [EoT]) and Week 20 (Follow up [4 weeks posttreatment]); Cohorts C-F: Weekly through Week 24 (EoT) and Week 28 (Follow up [4 weeks posttreatment])
Mean of Weekly Hb Values <10.5, >13, and >14 g/dL During Weeks 13-17 and 18-25	The mean percentage of the scheduled weekly Hb values that were <10.5, >13, and >14 g/dL during Weeks 13-17 and 18-25 is presented.	Weeks 13-17 (all cohorts) and 18-25 (24-week treatment cohorts only)
Number (%) of Participants Requiring Rescue Therapy	Rescue treatment included recombinant erythropoiesis-stimulating agent (ESA), red blood cell transfusion (in the absence of a known bleeding episode or surgical blood loss), or intravenous (IV) Iron	Baseline up to Week 28 (end of study)
Number (%) of Participants Requiring Therapeutic Phlebotomy		Baseline up to Week 28 (end of study)
Number (%) of Participants Withdrawn From the Study Due to Inadequate Efficacy		Baseline up to Week 28 (end of study)
Number (%) of Participants With Dose Changes During Weeks 1-4, 5-12, 13-16, and 17-24	Dose changes include dose reductions, dose increases, and dose holds.	Weeks 1-4, 5-12, and 13-16 (all cohorts) and Weeks 17-24 (24-week treatment cohorts only)
Weekly Total Dose and Cumulative Total Dose (mg/kg) When First Achieving Hb Response (Hb Increase ≥1 g/dL From Baseline and Hb ≥11 g/dL)		Cohorts A and B: Weekly through Week 16 (end of treatment); Cohorts C-F: Weekly through Week 24 (end of treatment)
Mean Weekly Dose After Achieving First Hb Response (Hb Increase ≥1 g/dL From Baseline and Hb ≥11 g/dL)		Cohorts A and B: Weekly through Week 16 (end of treatment); Cohorts C-F: Weekly through Week 24 (end of treatment)
Change From Baseline in Hb Stratified by Baseline Ferritin >100 Nanograms/Milliliter (ng/mL) and Transferrin Saturation >20% at Week 16 and Week 24	Baseline was defined as the mean of the last 3 available values predose.	Baseline, Weeks 16 (Cohorts A and B End of Treatment) and Week 24 (Cohorts C-F End of Treatment)

Collaborators and Investigators

• Sponsor: FibroGen
• Collaborators: Astellas Pharma Inc

Publications and helpful links

General Publications

• Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2.

Study record dates

Study Major Dates

• Study Start (Actual): October 29, 2010
• Primary Completion (Actual): June 13, 2012
• Study Completion (Actual): June 13, 2012

Study Registration Dates

• First Submitted: November 16, 2010
• First Submitted That Met QC Criteria: November 18, 2010
• First Posted (Estimate): November 19, 2010

Study Record Updates

• Last Update Posted (Actual): February 10, 2022
• Last Update Submitted That Met QC Criteria: January 17, 2022
• Last Verified: January 1, 2022

More Information

Terms related to this study

• Keywords: Erythropoietin; Anemia; Chronic Kidney Disease; CKD; Kidney; Renal; Hb; Oral anemia treatment; Hemoglobin levels; Blood count; Predialysis; Pre-dialysis; Non-dialysis
• Additional Relevant MeSH Terms: Urologic Diseases; Hematologic Diseases; Renal Insufficiency; Kidney Diseases; Renal Insufficiency, Chronic; Anemia
• Other Study ID Numbers: FGCL-4592-041